T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma

Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients

Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.

Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives

Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma

Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines